RAPT — Rapt Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $276.66m
- $117.80m
- 30
- 20
- 15
- 10
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 77.4 | 112 | 190 | 249 | 159 |
Prepaid Expenses | |||||
Total Current Assets | 80.5 | 116 | 193 | 253 | 162 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.71 | 2.98 | 2.74 | 9.48 | 7.68 |
Other Long Term Assets | |||||
Total Assets | 84.6 | 119 | 199 | 266 | 173 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.26 | 11.7 | 9.6 | 14.2 | 21.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.5 | 14.8 | 12.3 | 21 | 26.3 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 73.1 | 104 | 186 | 245 | 147 |
Total Liabilities & Shareholders' Equity | 84.6 | 119 | 199 | 266 | 173 |
Total Common Shares Outstanding |